Scientific and Educational Center 'Molecular Bases of Interaction of Microorganisms and Human' of the World-Class Research Center 'Center for Personalized Medicine', Institute of Experimental Medicine, 197376 Saint-Petersburg, Russia.
Department of Internal Diseases, Clinical Pharmacology and Nephrology, North-Western State Medical University Named after I.I. Mechnikov, Ministry of Health of the Russian Federation, 195067 Saint-Petersburg, Russia.
Benef Microbes. 2023 Apr 18;14(2):119-130. doi: 10.3920/BM2022.0053. Epub 2023 Mar 27.
Intestinal microbiota correction in the therapy of irritable bowel syndrome (IBS) is an important medical problem. We conducted a laboratory and pilot clinical trial to investigate the effect of autoprobiotic bacteria, indigenous bifidobacteria and enterococci isolated from faeces and grown on artificial media to use as personified food additives in IBS treatment. Convincing evidence of the clinical efficacy of autoprobiotic was demonstrated by the disappearance of dyspeptic symptoms. The microbiome of patients with IBS was compared to a group of healthy volunteers and changes in the microbiome after autoprobiotic use were detected by quantitative polymerase chain reaction and 16S rRNA metagenome analysis. The possibility of reducing opportunistic microorganisms in the treatment of IBS with autoprobiotics has been convincingly proven. The quantitative content of enterococci in the intestinal microbiota was higher in IBS patients than in healthy volunteers and increased after therapy. An increase in the relative abundance of genera and a decrease in the relative abundance of spp. were found at the end of therapy. A metabolome study which was performed by gas chromatography and mass spectrometry demonstrated an increase in the content of oxalic acid, a decrease of dodecanoate, lauric acid, and other metabolome components after taking autoprobiotics. Some of these parameters correlated with the relative abundances of spp., spp., and spp. representative of the microbiome. Apparently, they reflected the peculiarities of metabolic compensation and changes in the microbiota. Therefore, the use of autoprobiotics for treatment of IBS may lead to a stable positive clinical effect, associated with compensatory changes in the intestinal microbiota, and accompanied by corresponding changes in metabolic processes in the organism.
肠道微生物群纠正在肠易激综合征（IBS）的治疗中是一个重要的医学问题。我们进行了实验室和试点临床试验，以研究从粪便中分离出来并在人工培养基上生长的自体益生菌、本土双歧杆菌和肠球菌作为 IBS 治疗个性化食品添加剂的效果。自体益生菌的临床疗效令人信服，其消化不良症状消失。通过定量聚合酶链反应和 16S rRNA 宏基因组分析，比较了 IBS 患者和健康志愿者的微生物组，并检测了使用自体益生菌后微生物组的变化。用自体益生菌治疗 IBS 时减少机会性微生物的可能性已得到令人信服的证明。肠易激综合征患者肠道微生物群中的肠球菌定量含量高于健康志愿者，治疗后增加。治疗结束时，发现属的相对丰度增加，而 spp.的相对丰度减少。通过气相色谱和质谱进行的代谢组学研究表明，服用自体益生菌后，草酸的含量增加，十二烷酸、月桂酸和其他代谢组成分的含量减少。其中一些参数与 spp.、 spp.和 spp.的相对丰度相关，它们代表了微生物群。显然，它们反映了代谢补偿和微生物群变化的特点。因此，使用自体益生菌治疗 IBS 可能会导致稳定的积极临床效果，与肠道微生物群的代偿性变化相关，并伴有机体代谢过程的相应变化。
